NASDAQ · Biotechnology

STOK (STOK) Stock

$32.19 +0.81% NASDAQ: STOK Healthcare

Valuation

MetricValue
Price$32.19
Market Cap$2.08B
P/E Ratio-10.47
P/B Ratio5.43
P/S Ratio58.40
EPS (TTM)$-0.12
52-Week High$40.22
52-Week Low$11.17
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-45.58%
ROA-27.24%
ROCE-5.97%
Gross Margin90.36%
Operating Margin-5.77%
Net Margin-5.29%
Debt/Equity0.01
Current Ratio5.28

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$12.0M$9.0M$37.0M$184.0M
Operating Profit$-86.0M$-104.0M$-115.0M$-101.0M$-21.0M
Net Profit$-86.0M$-101.0M$-105.0M$-89.0M$-7.0M
EPS$-2.34$-2.60$-2.38$-1.65$-0.12
Op Margin—-841.2%-1307.2%-277.3%-11.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$239.0M$256.0M$228.0M$272.0M$418.0M
Total Liabilities$21.0M$71.0M$69.0M$43.0M$66.0M
Cash$145.0M$114.0M$191.0M$128.0M$84.0M
Borrowings$2.0M$2.0M$2.0M$2.0M$0

Latest News

Ionis Begins Dosing in Phase I/II Dravet Syndrome Study Zacks · Jul 14, 2026 Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer Business Wire · Jul 13, 2026 Stoke Therapeutics Completes Enrollment in Phase 3 Study of Zorevunersen for Dravet Syndrome Treatment MT Newswires · Jun 30, 2026 Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome Business Wire · Jun 30, 2026 Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire · Jun 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-67.0M$-32.0M$-81.0M$-87.0M$46.0M
Investing Cash Flow$-78.0M$-50.0M$104.0M$-108.0M$-187.0M
Financing Cash Flow$0$1.0M$1.0M$2.0M$0
Net Cash Flow$-142.0M$-31.0M$78.0M$-63.0M$-44.0M
Free Cash Flow$-68.0M$-36.0M$-83.0M$-87.0M$45.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-11.34
EV / EBITDA-9.17
FCF Yield-7.30%
Quick Ratio8.99
Interest Coverage—
Return 1Y116.88%
Return 3Y352.86%
Return 5Y-11.75%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARDX $5.09 +0.49% 11.04 $1.26B 0.00%
BCRXBioCryst Pharmaceuticals, Inc. $9.75 +4.39% -5.40 $2.48B 0.00%
NTLA $10.89 +2.06% -3.55 $1.22B 0.00%
NVAXNovavax, Inc. $7.61 +2.01% -13.81 $1.25B 0.00%
PHVS $32.62 -3.05% -9.75 $2.28B 0.00%

About STOK

STOK stock trades at $32.19 with a market capitalization of $2.08B. The stock is valued at a price-to-earnings (P/E) ratio of -10.47, price-to-book of 5.43, price-to-sales of 58.40. Over the past 52 weeks the stock has ranged between $11.17 and $40.22, and currently trades 20.0% below its 52-week high.

On profitability, STOK generates a return on equity (ROE) of -45.58%, return on capital employed of -5.97%, an operating margin of -5.77%, a net profit margin of -5.29%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides